Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple antigen specific cell therapy - HengRui YuanZheng Biotechnology

Drug Profile

Multiple antigen specific cell therapy - HengRui YuanZheng Biotechnology

Alternative Names: Cytotoxic T-cell therapy - HengRui YuanZheng; Dendritic cell therapy - HengRui YuanZheng; MASCT I; MASCT-1; Multiple target antigen stimulating cell therapy-I; Multiple-antigen specific cell therapy-I; Neo-MASCT

Latest Information Update: 29 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HengRui YuanZheng Bio-Technology
  • Developer Beijing Cancer Hospital; HengRui YuanZheng Bio-Technology; SYZ Cell Therapy
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Urogenital cancer
  • Phase I/II Solid tumours
  • Phase I Liver cancer
  • No development reported Gastric cancer

Most Recent Events

  • 29 Feb 2024 HengRui YuanZheng Bio-Technology plans a phase II trial for Soft tissue sarcoma (Metastatic disease, Late stage disease, Inoperable/Unresectable, Combination therapy, Recurrent, First line therapy) in China (parenteral) in February 2024 (NCT06277154)
  • 01 Nov 2023 Phase-I clinical trials in Liver cancer (IV) prior to October 2023 (HengRui YuanZheng Bio-Technology pipeline, October 2023)
  • 01 Nov 2023 Phase-II clinical trials in Urogenital cancer (IV) prior to October 2023 (HengRui YuanZheng Bio-Technology pipeline, October 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top